diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5937diaendo-5937Research ArticleСтатьиArticlesУровень гликемии и прогноз острых коронарных синдромов у больных сахарным диабетом 2 типаUroven' glikemii i prognoz ostrykh koronarnykh sindromov u bol'nykh sakharnym diabetom 2 tipaИвановаЛ АIvanovaL Аinfo@endojournals.ruГОУ ВПО Кубанский государственный медицинский университет, КраснодарRussian Federation200815032008111№1 (2008)1114Copyright © Иванова Л.А., 20082008Иванова Л.А.Ivanova L.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5937

Цель исследования ? сравнить прогностическое влияние интенсивного метаболического контроля гликлазидом, микронизированным глибенкламидом и инсулином, поддерживающих уровень гликемии натощак от 4,4 до 7,8 ммоль/л, у больных с ОКС, осложнившим течение СД 2. Материалы и методы. В исследование было включено 214 больных (93 мужчины и 121 женщина) с ОКС и подъемами сегмента ST, а также 308 пациентов с ОКС без подъемов сегмента ST. Контролируемая терапия продолжалась в течение года. Регистрировались возникавшие осложнения и смертность на этапе стационарного лечения, через 3 и 12 мес. Результаты и обсуждение. интенсивный гликемический контроль, обеспечивающий уровень гликемии от 4,4 до 7,8 ммоль/л, достигающийся с помощью перорального приема производных сульфонилмочевины гликлазида или глибенкламида, не уступает инсулинотерапии во влиянии на частоту осложнений и прогноз у больных СД 2, осложнившимся развитием ОКС с подъемами или без подъемов сегмента ST. Выводы.

сахарный диабеткоронарный синдромгликлазидглибенкламидReferencesВолков В.И., Серик С.А. Ишемическая болезнь сердца при сахарном диабете 2 типа: эпидемиология, патофизиология и профилактика. Междунар мед жур 2006; 4: 41-47.Волков В.И., Серик С.А. Ишемическая болезнь сердца при сахарном диабете 2 типа: эпидемиология, патофизиология и профилактика. Междунар мед жур 2006; 4: 41-47.Aronson D., Rayfield E.J. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002; 1: 1-9.Aronson D., Rayfield E.J. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002; 1: 1-9.Morgan K.P., Kapur A., Beatt K.J. Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. Heart 2004; 90: 732-738.Morgan K.P., Kapur A., Beatt K.J. Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. Heart 2004; 90: 732-738.Wei M., Gaskill S., Haffner S. et al. Effect of diabetes and level of glycemia on all-cause and cardiovascular mortality. The Sun Antonio Heart Study. Diabetes Care 1998; 21: 1167-1172.Wei M., Gaskill S., Haffner S. et al. Effect of diabetes and level of glycemia on all-cause and cardiovascular mortality. The Sun Antonio Heart Study. Diabetes Care 1998; 21: 1167-1172.Abbasi F., Brown B.W.Jr., Lamendola C. et al. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 937-943.Abbasi F., Brown B.W.Jr., Lamendola C. et al. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 937-943.Lehto S., Ronnemaa T., Pyorala K., Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia 2000; 43: 148-155.Lehto S., Ronnemaa T., Pyorala K., Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia 2000; 43: 148-155.Franklin K., Goldberg R.J., Spencer F. et al. for the GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004; 164: 1457-1463.Franklin K., Goldberg R.J., Spencer F. et al. for the GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004; 164: 1457-1463.Peterson P., Spertus J., Magid D. et al. The impact of diabetes on oneyear health status outcomes following acute coronary syndromes. BMC Cardiovasc Disord 2006; 6: 41-48.Peterson P., Spertus J., Magid D. et al. The impact of diabetes on oneyear health status outcomes following acute coronary syndromes. BMC Cardiovasc Disord 2006; 6: 41-48.Malmberg K., Ryden L., Efendic S. et al. Randomised trial of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study). Effect on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.Malmberg K., Ryden L., Efendic S. et al. Randomised trial of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study). Effect on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.Brady P.A., Terzic A. The sulfonylurea controversy: more questions from the heart. Am J Coll Cardiol 1998; 31: 950-956.Brady P.A., Terzic A. The sulfonylurea controversy: more questions from the heart. Am J Coll Cardiol 1998; 31: 950-956.Gribble F.M., Ashcroft F.M. Differential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide. Diabetologia 1999; 42: 845-848.Gribble F.M., Ashcroft F.M. Differential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide. Diabetologia 1999; 42: 845-848.McNulty P.H., Pfau S., Deckelbaum L.I. Effect of plasma insulin level on myocardial blood flow and its mechanism of action. Am J Cardiol 2000; 85: 161-165.McNulty P.H., Pfau S., Deckelbaum L.I. Effect of plasma insulin level on myocardial blood flow and its mechanism of action. Am J Cardiol 2000; 85: 161-165.Parsonage W.A., Hetmanski D., Cowley A.J. Beneficial haemodynamic effects of insulin in chronic heart failure. Heart 2001; 85: 508-513.Parsonage W.A., Hetmanski D., Cowley A.J. Beneficial haemodynamic effects of insulin in chronic heart failure. Heart 2001; 85: 508-513.Davila-Roman V.G., Vedala G., Herrero P. et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 271-277.Davila-Roman V.G., Vedala G., Herrero P. et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 271-277.Smooke S., Horwich Т.В., Fonarow G.C. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005; 149: 168-174.Smooke S., Horwich Т.В., Fonarow G.C. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005; 149: 168-174.Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre diabetes, and cardiovascular diseases: full text. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 9: Suppl C: C3-C74.Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre diabetes, and cardiovascular diseases: full text. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 9: Suppl C: C3-C74.Bassand J.-P., Hamm C.W., Adrissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-STSegment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007; 28: 1598-1660.Bassand J.-P., Hamm C.W., Adrissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-STSegment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007; 28: 1598-1660.Malmberg K., Ryden L., Wedel H. et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-661.Malmberg K., Ryden L., Wedel H. et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-661.

The authors declare that there are no conflicts of interest present.